Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03943056
Recruitment Status : Recruiting
First Posted : May 9, 2019
Last Update Posted : June 18, 2019
Sponsor:
Information provided by (Responsible Party):
Biogen

Brief Summary:
This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of BIIB091 in healthy participants.This study will also determine the effect of food on the single oral dose pharmacokinetic (PK).

Condition or disease Intervention/treatment Phase
Healthy Volunteer Drug: BIIB091 Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 64 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Blinded Study
Primary Purpose: Treatment
Official Title: A Phase 1, Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants
Actual Study Start Date : May 13, 2019
Estimated Primary Completion Date : December 24, 2019
Estimated Study Completion Date : December 24, 2019

Arm Intervention/treatment
Experimental: Single Ascending Dose (SAD): Cohort 1A
Participants will receive dose level 1 of BIIB091 or placebo, orally, while fasting on Day 1.
Drug: BIIB091
Administered as specified in the treatment arm.

Drug: Placebo
Administered as specified in the treatment arm.

Experimental: (SAD): Cohort 2A
Participants will receive dose level 2 of BIIB091 or placebo, orally, while fasting on Day 1.
Drug: BIIB091
Administered as specified in the treatment arm.

Drug: Placebo
Administered as specified in the treatment arm.

Experimental: (SAD): Cohort 3A
Participants will receive dose level 3 of BIIB091 or placebo, orally, while fasting on Day 1, then again following a 7 day washout and high-fat meal.
Drug: BIIB091
Administered as specified in the treatment arm.

Drug: Placebo
Administered as specified in the treatment arm.

Experimental: (SAD): Cohort 4A
Participants will receive dose level 4 of BIIB091 or placebo, orally, while fasting on Day 1.
Drug: BIIB091
Administered as specified in the treatment arm.

Drug: Placebo
Administered as specified in the treatment arm.

Experimental: (SAD): Cohort 5A
Participants will receive dose level 5 of BIIB091 or placebo, orally, while fasting on Day 1.
Drug: BIIB091
Administered as specified in the treatment arm.

Drug: Placebo
Administered as specified in the treatment arm.

Experimental: Multiple Ascending Dose (MAD): Cohort 1B
Participants will receive dose level 1 of BIIB091 or placebo, orally, twice daily (BID) for 13 days, and a single dose on Day 14.
Drug: BIIB091
Administered as specified in the treatment arm.

Drug: Placebo
Administered as specified in the treatment arm.

Experimental: (MAD): Cohort 2B
Participants will receive dose level 2 of BIIB091 or placebo, orally, BID for 13 days, and a single dose on Day 14.
Drug: BIIB091
Administered as specified in the treatment arm.

Drug: Placebo
Administered as specified in the treatment arm.

Experimental: (MAD): Cohort 3B
Participants will receive dose level 3 of BIIB091 or placebo, orally, BID for 13 days, and a single dose on Day 14.
Drug: BIIB091
Administered as specified in the treatment arm.

Drug: Placebo
Administered as specified in the treatment arm.




Primary Outcome Measures :
  1. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Baseline up to Day 9 for SAD Cohorts; Baseline up to Day 24 for MAD Cohorts ]
    An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose: results in death, in the view of the Investigator, places the participant at immediate risk of death (a life-threatening event), however, this does not include an event that, had it occurred in a more severe form, might have caused death; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect or is a medically important event.


Secondary Outcome Measures :
  1. Area Under the Curve from Time 0 to the Time of the Last Measurable Concentration (AUClast) [ Time Frame: Baseline and multiple timepoints up to Day 3 for SAD Cohorts; Baseline and multiple timepoints up to Day 16 for MAD Cohorts ]
  2. Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUCinf) [ Time Frame: Baseline and multiple timepoints up to Day 3 ]
  3. Maximum Observed Concentration (Cmax) [ Time Frame: Baseline and multiple timepoints up to Day 3 for SAD Cohorts; Baseline and multiple timepoints up to Day 14 for MAD Cohorts ]
  4. Time to Reach Maximum Observed Concentration (Tmax) [ Time Frame: Baseline and multiple timepoints up to Day 3 for SAD Cohorts; Baseline and multiple timepoints up to Day 14 for MAD Cohorts ]
  5. Elimination Half-Life (t½) [ Time Frame: Baseline and multiple timepoints up to Day 3 for SAD Cohorts; Baseline and multiple timepoints up to Day 16 for MAD Cohorts ]
  6. Apparent Total Body Clearance (CL/F) [ Time Frame: Baseline and multiple timepoints up to Day 3 for SAD Cohorts; Baseline and multiple timepoints up to Day 16 for MAD Cohorts ]
  7. Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) [ Time Frame: Baseline and multiple timepoints up to Day 3 for SAD Cohorts; Baseline and multiple timepoints up to Day 16 for MAD Cohorts ]
  8. Amount of BIIB091 Excreted in Urine per Sampling Interval (Aeu) [ Time Frame: Baseline and multiple timepoints up to Day 3 ]
  9. Percentage of BIIB091 Excreted in Urine per Sampling Interval (%Feu) [ Time Frame: Baseline and multiple timepoints up to Day 3 ]
  10. Renal clearance (CLr) [ Time Frame: Baseline and multiple timepoints up to Day 3 ]
  11. Area Under the Concentration-Time Curve Within a Dosing Interval (AUCtau) [ Time Frame: Baseline and multiple timepoints up to Day 16 ]
  12. Accumulation Ratio (R) [ Time Frame: Baseline and multiple timepoints up to Day 16 ]
  13. Trough concentration (Ctrough) [ Time Frame: Baseline and multiple timepoints up to Day 16 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Key Inclusion Criteria:

  • Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use confidential health information in accordance with applicable participant privacy regulations.
  • Have a body mass index between 18 and 30 kg/m2, inclusive.
  • All male participants must practice highly effective methods of contraception and not donate sperm during the study and for at least 1 spermatogenic cycle (90 days) after administration of last dose of study treatment.
  • All female participants of childbearing potential must practice highly effective methods of contraception and not donate eggs during the study and for at least 90 days after their last dose of study treatment.
  • Must be in good health as by the Investigator, based on medical history and screening evaluations.

Key Exclusion Criteria:

  • History of any clinically significant cardiac, endocrine, gastrointestinal, hematologic,hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease, or other major disease, as determined by the Investigator.
  • History of severe allergic or anaphylactic reactions, or of any allergic reactions that in the opinion of the Investigator are likely to be exacerbated by any component of the study treatment.
  • History of, or ongoing, malignant disease, including solid tumors and hematologic malignancies (with the exception of basal cell carcinomas and squamous cell carcinomas that have been completely excised and considered cured at least 12 months prior to Check-in).
  • Current enrollment or plan to enroll in any other drug, biological, device, or clinical study, or treatment with an investigational drug or approved therapy for investigational use within 30 days prior to Check-in, or 5 half-lives of the drug or therapy, whichever is longer.
  • Breastfeeding, pregnant, or planning to become pregnant during study participation.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03943056


Contacts
Layout table for location contacts
Contact: US Biogen Clinical Trial Center 866-633-4636 clinicaltrials@biogen.com
Contact: Global Biogen Clinical Trial Center clinicaltrials@biogen.com

Locations
Layout table for location information
United States, Texas
Research Site Recruiting
Dallas, Texas, United States, 75247
Sponsors and Collaborators
Biogen
Investigators
Layout table for investigator information
Study Director: Medical Director Biogen

Layout table for additonal information
Responsible Party: Biogen
ClinicalTrials.gov Identifier: NCT03943056     History of Changes
Other Study ID Numbers: 257HV101
First Posted: May 9, 2019    Key Record Dates
Last Update Posted: June 18, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on http://clinicalresearch.biogen.com/
URL: http://www.biogenclinicaldatarequest.com

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No